This contrasts with a prior clinical study where treatment with sorafenib, a multikinase inhibitor targeting mainly VEGF receptors, in RCC led to decreased 111In-bevacizumab uptake and did not correlate with VEGF levels [18]. The gene discussed is VEGFA; the disease is renal cell adenocarcinoma.